The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres – results of CysTiming Poland study
Journal Title: Central European Journal of Urology - Year 2014, Vol 67, Issue 4
Abstract
Introduction The aim of the study was to assess the waiting time, from establishing the indications for radical cystectomy to surgery, in patients with urothelial carcinoma of the bladder at different Polish urological centres and to determine its influencing factors. Material and methods Retrospective analysis of data was performed on all consecutive radical cystectomies, performed in 2008–2012, at 10 Polish urological centres. The waiting time of patients from establishing the indications for radical cystectomy to surgery, as well as factors potentially influencing this time, were assessed. University (3), provincial (3) and regional (4) hospitals were defined as the 3rd, 2nd and 1st level referral hospitals, respectively. Results A total of 575 patients qualified for radical cystectomy due to muscle invasive urothelial carcinoma of the bladder (MIBC, 68% of cases) or failure of previous treatment of non–muscle invasive urothelial carcinoma of the bladder (NMIBC, 32%) were included in the analysis. The average time after the establishment of indications to surgery was 73.4 days, with a median of 56 days. In the case of 121 patients (22.1%), the waiting time exceeded 90 days. Significant differences in waiting time were found when the hospital referral levels were taken into consideration. In the 3rd level referral hospitals the median time for cystectomy was 61.5 days (p = 0.035), in the 2nd level referral hospitals – 45 days (p = 0.000) and, in the 1st level referral hospitals – 58 days (p = 0.051). Conclusions The waiting time from establishing the indications for radical cystectomy to surgery for most cases in Poland does not exceed 90 days.
Authors and Affiliations
Sławomir Poletajew, Janusz Lisiński, Karol Moskal, Jacek Ornat, Kacper Renk, Michał Szlaga, Jakub Tworkiewicz, Dominik Wojtkowiak, Paweł Wołyniec, Krzysztof Woźniak, Łukasz Zapała, Piotr Radziszewski
Keywords
Related Articles
- EP ID EP356662
- DOI 10.5173/ceju.2014.04.art2
- Views 41
- Downloads 0
What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?
patients diagnosed with either idiopathic detrusor overactivity (IDO) or neurogenic detrusor overactivity (NDO). Material and methods Retrospective case–notes review of patients who were converted from 300IU to 200IU Ona...
AUTHOR’S REPLY
Author's Reply
The cardiovascular and gastrointestinal adverse effects of cyclooxygenase inhibitors seems to be a major concern that restricts their use in the treatment of urinary bladder dysfunction
Editorial referring to the paper: Gokkaya CS, Aktas BK, Ozden C, Bulut S, Karabakan M, Erkmen AE, Memis A. Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms. Cent Eur...
Author's Reply
Author's reply.
Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia
Introduction Strong epidemiologic evidence supports correlation between lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED). The link has biologic plausibility given...